Clinical Trial Update: Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer. [EARLY_Phase 1]

View source ↗

Summary

This update notes the termination of an early-phase safety study evaluating an antibody for pancreatic cancer to determine the appropriate dose.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Pancreatic Cancer | EARLY_Phase 1 | Status: TERMINATED